Farmas USA

Novavax Receives the Tech Council of Maryland's Chairman's Award

 

(GLOBE NEWSWIRE via COMTEX) --GAITHERSBURG, Md., May 12, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it received the Tech Council of Maryland's (TCM) Chairman's Award. The award was announced at the TCM Industry Award Celebration on May 11, 2016. 

The Chairman's Award is presented to a member company or individual that best exemplifies excellence in Maryland's technology or life science industry.  The Award recognizes a company that is a pillar in the community, not only through market success or job creation, but by consistently giving back, getting involved and advancing the climate for innovation.

"Novavax is the embodiment of what we look for when selecting an honoree for the Chairman's award. The company has built a successful business, employing 450 people in Maryland who are developing vaccines that positively impact global health, and has played an important role in fostering growth of the state's life sciences community," said Rene B. LaVigne, TCM chairman-elect and president and CEO of Iron Bow Technologies. "TCM appreciates Novavax's significant contributions to the association, the state's economy and innovations in healthcare."

"I am honored to accept this award on behalf of the entire Novavax team," said Stanley C. Erck, President and CEO, Novavax. "The Tech Council of Maryland facilitates a collaborative community of technology and life science companies who aim to make an impact in our region and beyond. We are thrilled that this award recognizes the hard work and dedication of our more than 450 SuperNovas, our groundbreaking achievements in developing novel vaccines and our commitment to the Maryland life science and technology community."

Bueno al menos una noticia buena a ver si la toma la acción en precio
NVAX

eso son cosas entre empresas, nada que afecte a la cotizacion
NVAX

AMRN

initiated at Buy at Jefferies, PT $3.50

http://www.streetinsider.com/Analyst+Comments/Jefferies+Assumes+Amarin+Corporation+%28AMRN%29+at+Buy/11620892.html

Aqui esta el doc Jefferies

https://drive.google.com/file/d/0B1gB2YESBJV7eTJ0YlBUaExUZmc/view?usp=sharing

AMRN

Bayer estudia BO por 40 Billones, casi na ...

http://www.bloomberg.com/news/articles/2016-05-12/bayer-said-to-explore-bid-for-40-billion-seed-company-monsanto

"Horizon Pharma plc Announces Settlement of PENNSAID(R) (diclofenac sodium topical solution) 2% w/w Patent Litigation With Teligent, Inc."
"Today announced that its affiliates have entered into a settlement and license agreement with Teligent, Inc. to resolve pending patent litigation involving PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID® 2%).

Under the settlement and license agreement, Horizon has granted Teligent the non-exclusive right to market a generic diclofenac sodium topical 2% w/w solution in the United States under Teligent's Abbreviated New Drug Application (ANDA) beginning January 10, 2029 or earlier under certain circumstances.

The agreement follows the May 2, 2016, entry of a stipulation of dismissal without prejudice of all lawsuits filed by Horizon in the U.S. District Court for the District of New Jersey relating to the ANDA filed by Teligent with the U.S. Food and Drug Administration for a generic version of PENNSAID 2%."

A ver si esto la anima un poco.

"Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of Additional Notice of Allowance With Claims Covering KRYSTEXXA(R) (pegloticase)"
"Today announced it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 13/379,704 (U.S. publication number 2012-0301454), entitled "Methods and Kits for Predicting Infusion Reaction Risk and Antibody-Mediated Loss of Response by Monitoring Serum Uric Acid During Pegylated Uricase Therapy" that covers Horizon's U.S. approved medicine KRYSTEXXA® (pegloticase).

The Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire June 25, 2030."

Esta es de ayer.